{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:57:32Z","timestamp":1788623852138,"version":"build-2803163510"},"reference-count":24,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Hereditary angioedema (HAE) is a rare, potentially fatal genetic disorder characterized by unpredictable attacks of bodily swelling that substantially impair patients\u2019 quality of life (QoL). Lanadelumab is approved for long-term prophylaxis (LTP) in patients\n with HAE; however, there are limited real-world data that compare lanadelumab with other treatments to guide patient care.\n                    <jats:bold>Objective:<\/jats:bold>\n                    The objective was to describe real-world QoL and related outcomes of patients with HAE who received lanadelumab versus other LTP.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Data were drawn from a real-world, cross-sectional survey of physicians and their consulting patients with HAE in the United States from January 2023 to January 2024. Physician-reported attack and disease severity, pain, fatigue, QoL, and patient-reported outcomes were\n compared among patients receiving lanadelumab or other LTP.\n                    <jats:bold>Results:<\/jats:bold>\n                    Physicians reported data on 86 patients treated with lanadelumab and 84 treated with other LTP. A statistically significantly higher proportion of patients receiving lanadelumab had no chronic pain (58.1%)\n and no chronic fatigue (51.2%) at the time of the survey than those receiving other LTP (38.1% [p = 0.0023] and 34.9% [p = 0.0037], respectively). More patients receiving lanadelumab had \u201cvery good\u201d physician-reported QoL and less patient-reported QoL impairment at the time of\n the survey compared with those receiving other LTP (p = 0.0102). A higher proportion of patients receiving lanadelumab compared with other LTP reported complete satisfaction overall with their treatment (30.2% versus 17.9%, respectively; p = 0.0144) and complete satisfaction with the efficacy\n of their treatment (44.2% versus 11.9%, respectively; p &lt; 0.0001).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In this real-world study, physicians reported a higher proportion of patients receiving lanadelumab had no chronic pain or fatigue compared with those receiving other LTP. Both physicians\n and patients reported higher QoL in those receiving lanadelumab. Continued real-world research in patients with HAE to further assess the effect of lanadelumab on QoL will help guide patient care.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.250104","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:35:38Z","timestamp":1773722138000},"page":"102-111","source":"Crossref","is-referenced-by-count":3,"title":["Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis"],"prefix":"10.2500","volume":"47","author":[{"given":"Mark","family":"Davis-Lorton","sequence":"first","affiliation":[{"name":"From the ENT and Allergy Associates, Tarrytown, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Soteres","sequence":"additional","affiliation":[{"name":"Asthma & Allergy Associates, Colorado Springs, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[{"name":"Asthma & Allergy Associates, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hall","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Connolly","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fox","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Sing","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob G.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Juethner","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","first-page":"S292","article-title":"Severity of hereditary angioedema, prevalence, and diagnostic considerations","volume":"24","author":"Bernstein","year":"2018","journal-title":"Am J Manag Care"},{"key":"B2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2249.2005.02726.x","article-title":"C1 inhibitor deficiency: consensus document","volume":"139","author":"Gompels","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","article-title":"Hereditary angioedema: an update on causes, manifestations and treatment","volume":"80","author":"Longhurst","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"B4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3949\/ccjm.80a.12073","article-title":"Recognizing and managing hereditary angioedema","volume":"80","author":"Tse","year":"2013","journal-title":"Cleve Clin J Med"},{"key":"B5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2500\/aap.2017.38.4087","article-title":"Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden","volume":"38","author":"Nordenfelt","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","article-title":"TAKHZYRO (lanadelumab-flyo) [Highlights of prescribing information] injection, for subcutaneous use."},{"key":"B9","article-title":"TAKHZYRO (INN-lanadelumab) [Summary of product characteristics]"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0653","article-title":"Treatment of hereditary angioedema","volume":"31","author":"Caballero","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"B13","doi-asserted-by":"crossref","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"B14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/all.12007","article-title":"Development and construct validation of the angioedema quality of life questionnaire","volume":"67","author":"Weller","year":"2012","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"B17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaci.2021.05.016","article-title":"Consensus on treatment goals in hereditary angioedema: a global Delphi initiative","volume":"148","author":"Maurer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.anai.2023.03.028","article-title":"Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema","volume":"131","author":"Lumry","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"AB131","DOI":"10.1016\/j.jaci.2022.12.413","article-title":"Effectiveness, safety, and patient-reported outcomes (PROs) in patients with hereditary angioedema (HAE) from the United States and Canada treated with lanadelumab: 24-month data from the EMPOWER study","volume":"151","author":"Wedner","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2500\/aap.2013.34.3685","article-title":"The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe","volume":"35","author":"Caballero","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"B23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12016-016-8575-2","article-title":"The humanistic, societal, and pharmaco-economic burden of angioedema","volume":"51","author":"Longhurst","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpain.2011.10.014","article-title":"The perception of pain in others: how gender, race, and age influence pain expectations","volume":"13","author":"Wandner","year":"2012","journal-title":"J Pain"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000002\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:31:00Z","timestamp":1775536260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.250104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["1088-5412(20260301)47:2L.102;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.250104","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}